Stratified analyses between PAD14 rs2240340 G/A, MBD4 rs140693 G/A, and MBD4 rs2005618 T/C polymorphisms and risk of rheumatoid arthritis.
| Variable | PAD14 rs2240340 G/A* (case/control) | OR (95% CI) | MBD4 rs140693 G/A (case/control) | OR (95% CI) | MBD4 rs2005618 T/C (case/control) | OR (95% CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GG + GA | AA | GG + GA | AA | GG + GA | AA | GG + GA | AA | TT + TC | CC | TT + TC | CC | |
| Gender | ||||||||||||
| Male | 60/168 | 21/33 | 1.00 | 1.78 (0.96–3.32) | 72/170 | 9/31 | 1.00 | 0.69 (0.31–1.51) | 63/159 | 18/42 | 1.00 | 1.08 (0.58–2.02) |
| Female | 194/415 | 49/79 | 1.00 | 1.33 (0.89–1.97) | 201/416 | 37/79 | 1.00 | 0.97 (0.63–1.48) | 192/382 | 51/113 | 1.00 | 0.90 (0.62–1.30) |
| Age, yrs | ||||||||||||
| < 55 | 130/281 | 32/62 | 1.00 | 1.12 (0.69–1.79) | 130/285 | 28/58 | 1.00 | 1.06 (0.64–1.74) | 125/263 | 37/80 | 1.00 | 0.97 (0.62–1.52) |
| ≥ 55 | 124/302 | 38/50 | 1.00 | 1.85 (1.16–2.96) | 143/301 | 18/52 | 1.00 | 0.73 (0.41–1.29) | 130/278 | 32/75 | 1.00 | 0.91 (0.57–1.45) |
| CRP status | ||||||||||||
| Positive | 127/583 | 36/112 | 1.00 | 1.48 (0.97–2.25) | 137/586 | 22/110 | 1.00 | 0.86 (0.52–1.40) | 123/541 | 40/155 | 1.00 | 1.14 (0.76–1.69) |
| Negative | 127/583 | 34/112 | 1.00 | 1.39 (0.91–2.14) | 136/586 | 24/110 | 1.00 | 0.94 (0.58–1.52) | 132/541 | 29/155 | 1.00 | 0.77 (0.49–1.19) |
| ACPA status | ||||||||||||
| Positive | 125/583 | 37/112 | 1.00 | 1.54 (1.01–2.34) | 135/586 | 24/110 | 1.00 | 0.95 (0.59–1.53) | 124/541 | 38/155 | 1.00 | 1.07 (0.71–1.60) |
| Negative | 129/583 | 33/112 | 1.00 | 1.33 (0.86–2.05) | 138/586 | 22/110 | 1.00 | 0.85 (0.52–1.39) | 131/541 | 31/155 | 1.00 | 0.83 (0.54–1.27) |
↵* Genotyping was successful in 324 cases and 695 controls for PAD14 rs2240340 G/A; 319 cases and 696 controls for MBD4 rs140693 G/A; and 324 cases and 696 controls for MBD4 rs2005618 T/C. We conducted stratification analyses only in PAD14 rs2240340 G/A since it is in complete linkage disequilibrium with PAD14 rs874881 C/G. ACPA: anticitrullinated protein antibody.